NO20003723L - Triazol- og imidazolderivater - Google Patents
Triazol- og imidazolderivaterInfo
- Publication number
- NO20003723L NO20003723L NO20003723A NO20003723A NO20003723L NO 20003723 L NO20003723 L NO 20003723L NO 20003723 A NO20003723 A NO 20003723A NO 20003723 A NO20003723 A NO 20003723A NO 20003723 L NO20003723 L NO 20003723L
- Authority
- NO
- Norway
- Prior art keywords
- lower alkyl
- pyridin
- hydroxy
- phenyl
- hydrogen
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- -1 hydroxy, phenyl Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000006193 alkinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 239000002981 blocking agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Foreliggende oppfinnelse angår forbindelser med den generelle formel R1 hvor R1 - R4 betyr uavhengig hydrogen, -CF3> -OCF3, OCHF2, -OCH2F, lavere alkyl, lavere alkoksy, halogen, hydroksy, fenyl, benzyl, amino, nitro, pyrrol-1-yl, lavere alkyl-sulfonyl, lavere alkyl-sulfanyl, cyano eller benzyloksy; eller R2 og R3 kan være sammen -0-(CH2)2-O-, -0-CH2-0-, -0-(CH2)2-, -(CH2)3- eller -CH=CH-CH=CH-; X betyr-N=,-N(R8)-eller-CH=; Y betyr -N=, =N-, -N(R8)- eller -CH=; hvor en av X eller Y har å være nitrogen; R5 betyr gruppen v hvor R6 og R7 betyr uavhengig av hverandre hydrogen, lavere alkyl, -C(0)-lavere alkyl, hydroksy-lavere alkyl, lavere alkenyl, -C(O)CH2OH eller R6 og R7 kan være sammen med the N-atom -(CH2)n-, -(CH2)2-O-(CH2)2-, -CH2-CH=CH-CH2,-CH2-CH[OC(0)CH3]-(CH2)2, -CH2-CH[NHC(O)CH3]-(CH2)2, -O-(CH2)3-, -CH2-CH(OCH3)-(CH2)2-, -CH2-CH(halogen)-(CH2)2-, -(CH2)2-CH(0- fenyl)-(CH2)2-, -(CH2)2-N(CHO)-(CH2)2-, -(CH2)2-N(COCH3HCH2)2-, -CH2-CH(OH> (CH2)3-, -(CH2)2-CH(OH)-(CH2)2- eller -(CH2)2-N(benzyl)-CH:)2-; n betyr 3 til 5; og R8 betyr hydrogen, lavere alkyl, lavere alkenyl, lavere alkinyl, -(CH2)m-O-lavere alkyl, -(CH2)m-OH, -(CH2)m-CHF2, -(CH2)m-CH2F, -(CH2)m-C(O)-lavere alkyl, -(CH2)m-C(0)0- lavere alkyl, -(CH2)m-CH(OH)-lavere alkyl, -(CH2)m-CH(OH)-(CH2)mOH, -(CH2)m-C6H5, hvilken fenylring eventuelt er substituert med lavere alkyl, lavere alkoksy eller hydroksy, -(CH2)m-C(=CH2)-lavere alkyl, -(CH2)m-cykloalkyl) -(CH2)m-CN, -(CH2)m-pyridin-4-yl, -(CH2)m-pyridin-3-yl eller -(CH2)m-pyridin-2-yl; m betyr O til 4; og deres farmasøytisk godtagbare syreaddisjonssalter. Disse forbindelser kan anvendes for behandling av sykdommer beslektet med NMDA reseptor-subtype selektive blokkeringsmidler.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99114313 | 1999-07-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20003723D0 NO20003723D0 (no) | 2000-07-20 |
| NO20003723L true NO20003723L (no) | 2001-01-22 |
Family
ID=8238635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20003723A NO20003723L (no) | 1999-07-21 | 2000-07-20 | Triazol- og imidazolderivater |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6265426B1 (no) |
| EP (1) | EP1070708B1 (no) |
| JP (1) | JP3628946B2 (no) |
| KR (1) | KR100383776B1 (no) |
| CN (1) | CN1148357C (no) |
| AR (1) | AR024790A1 (no) |
| AT (1) | ATE257827T1 (no) |
| AU (1) | AU773463B2 (no) |
| BR (1) | BR0003075A (no) |
| CA (1) | CA2314009C (no) |
| CO (1) | CO5190713A1 (no) |
| DE (1) | DE60007697T2 (no) |
| DK (1) | DK1070708T3 (no) |
| ES (1) | ES2211420T3 (no) |
| HR (1) | HRP20000482A2 (no) |
| HU (1) | HUP0002792A3 (no) |
| ID (1) | ID26599A (no) |
| IL (1) | IL137328A0 (no) |
| MA (1) | MA26747A1 (no) |
| MX (1) | MXPA00007069A (no) |
| NO (1) | NO20003723L (no) |
| NZ (1) | NZ505766A (no) |
| PE (1) | PE20010349A1 (no) |
| PL (1) | PL341616A1 (no) |
| PT (1) | PT1070708E (no) |
| SG (1) | SG98422A1 (no) |
| TR (1) | TR200002097A2 (no) |
| UY (1) | UY26253A1 (no) |
| ZA (1) | ZA200003680B (no) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6610723B2 (en) * | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| US7375136B2 (en) | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
| US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| WO2004037804A1 (en) * | 2002-10-22 | 2004-05-06 | Oscotec Inc. | Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same |
| US7084145B2 (en) * | 2002-10-25 | 2006-08-01 | Pfizer Inc. | Triazole compounds useful in therapy |
| CA2514363A1 (en) * | 2003-02-12 | 2004-08-26 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| AU2004309357B2 (en) * | 2003-12-22 | 2010-10-07 | Merck Sharp & Dohme Corp. | Alpha-hydroxy amides as bradykinin antagonists or inverse agonists |
| CA2551909C (en) * | 2004-02-12 | 2011-10-11 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
| NZ569329A (en) | 2006-01-30 | 2011-09-30 | Transtech Pharma Inc | Substituted imidazole derivatives and their use as PTPase inhibitors |
| JO3019B1 (ar) * | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| PL2118077T3 (pl) * | 2007-02-08 | 2015-05-29 | Synta Pharmaceuticals Corp | Związki triazolowe modulujące aktywność hsp90 |
| WO2008124092A2 (en) * | 2007-04-03 | 2008-10-16 | E. I. Du Pont De Nemours And Company | Substituted benzene fungicides |
| US20110158907A1 (en) * | 2007-04-19 | 2011-06-30 | The Trustees Of The Univeristy Of Pennsylvania | Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques |
| EA201070077A1 (ru) * | 2007-06-29 | 2010-08-30 | Эмори Юниверсити | Антагонисты nmda-рецепторов с нейропротективным действием |
| JO2784B1 (en) * | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
| CA2697974C (en) | 2007-10-18 | 2015-06-30 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4-triazoles |
| WO2009115547A1 (en) | 2008-03-19 | 2009-09-24 | Janssen Pharmaceutica Nv | Trisubstituted 1, 2, 4 -triazoiies as nicotinic acetylcholine receptor modulators |
| MX2010009649A (es) * | 2008-03-27 | 2010-12-17 | Evotecv Neurosciences Gmbh | Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda. |
| AR071763A1 (es) | 2008-05-09 | 2010-07-14 | Janssen Pharmaceutica Nv | Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos |
| RU2532394C1 (ru) * | 2013-10-29 | 2014-11-10 | Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") | ПРИМЕНЕНИЕ БРОМИДА 1-β-ФЕНИЛЭТИЛ)-4-АМИНО-1,2,4-ТРИАЗОЛИЯ (ГИПЕРТРИЛ) КАК АКТИВНОЙ ОСНОВЫ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ КОРРЕКЦИИ НАРУШЕНИЙ ФУНКЦИОНИРОВАНИЯ НИТРОКСИДЕРГИЧЕСКОЙ СИСТЕМЫ ОРГАНОВ-МИШЕНЕЙ ПРИ ГОМОЦИСТЕИНЕМИИ И ОСТРЫХ НАРУШЕНИЯХ МОЗГОВОГО КРОВООБРАЩЕНИЯ |
| BR112017003918B1 (pt) * | 2014-08-29 | 2022-05-03 | Fmc Corporation | Composto, composições e mistura herbicida e método para o controle do crescimento da vegetação |
| KR102512548B1 (ko) | 2017-12-22 | 2023-03-22 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물 |
| US12054464B1 (en) | 2023-10-23 | 2024-08-06 | King Faisal University | Methyl 4-((5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)methyl)benzoate as an antimicrobial compound |
| US11912670B1 (en) | 2023-10-25 | 2024-02-27 | King Faisal University | Ethyl 4-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)butanoate as an antimicrobial compound |
| CN118026948A (zh) * | 2024-01-31 | 2024-05-14 | 中国药科大学 | 三联芳环类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1579352A (en) * | 1977-05-06 | 1980-11-19 | Lepetit Spa | 3,5-disubstituted-1h-1,2,4-triazoles |
| DE19643037A1 (de) * | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| BR9810651A (pt) * | 1997-07-03 | 2000-10-03 | Neurogen Corp | Certos derivados de diarilimidazol; uma nova classe de ligantes npy especìficos |
| DE19816880A1 (de) * | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| JP2006512767A (ja) | 2003-01-02 | 2006-04-13 | ピー・デイ・エフ ソリユーシヨンズ インコーポレイテツド | 歩留まり改善 |
-
2000
- 2000-07-13 AT AT00114183T patent/ATE257827T1/de not_active IP Right Cessation
- 2000-07-13 ES ES00114183T patent/ES2211420T3/es not_active Expired - Lifetime
- 2000-07-13 EP EP00114183A patent/EP1070708B1/en not_active Expired - Lifetime
- 2000-07-13 PT PT00114183T patent/PT1070708E/pt unknown
- 2000-07-13 DE DE60007697T patent/DE60007697T2/de not_active Expired - Fee Related
- 2000-07-13 DK DK00114183T patent/DK1070708T3/da active
- 2000-07-17 AU AU48651/00A patent/AU773463B2/en not_active Ceased
- 2000-07-17 PE PE2000000707A patent/PE20010349A1/es not_active Application Discontinuation
- 2000-07-17 IL IL13732800A patent/IL137328A0/xx unknown
- 2000-07-17 CA CA002314009A patent/CA2314009C/en not_active Expired - Fee Related
- 2000-07-17 NZ NZ505766A patent/NZ505766A/en unknown
- 2000-07-18 SG SG200003981A patent/SG98422A1/en unknown
- 2000-07-19 CO CO00054541A patent/CO5190713A1/es not_active Application Discontinuation
- 2000-07-19 MA MA26026A patent/MA26747A1/fr unknown
- 2000-07-19 AR ARP000103702A patent/AR024790A1/es active IP Right Grant
- 2000-07-19 ID IDP20000607D patent/ID26599A/id unknown
- 2000-07-19 MX MXPA00007069A patent/MXPA00007069A/es unknown
- 2000-07-19 US US09/619,518 patent/US6265426B1/en not_active Expired - Fee Related
- 2000-07-19 TR TR2000/02097A patent/TR200002097A2/xx unknown
- 2000-07-20 UY UY26253A patent/UY26253A1/es not_active Application Discontinuation
- 2000-07-20 HU HU0002792A patent/HUP0002792A3/hu unknown
- 2000-07-20 HR HR20000482A patent/HRP20000482A2/hr not_active Application Discontinuation
- 2000-07-20 KR KR10-2000-0041592A patent/KR100383776B1/ko not_active Expired - Fee Related
- 2000-07-20 CN CNB001201816A patent/CN1148357C/zh not_active Expired - Fee Related
- 2000-07-20 NO NO20003723A patent/NO20003723L/no unknown
- 2000-07-20 ZA ZA200003680A patent/ZA200003680B/xx unknown
- 2000-07-21 JP JP2000220748A patent/JP3628946B2/ja not_active Expired - Fee Related
- 2000-07-21 BR BR0003075-9A patent/BR0003075A/pt not_active Application Discontinuation
- 2000-07-21 PL PL00341616A patent/PL341616A1/xx not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20003723L (no) | Triazol- og imidazolderivater | |
| JP2018524298A5 (no) | ||
| AU2134402A (en) | Antiviral agents | |
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| WO2001064639A3 (en) | Pde iv inhibiting amides, compositions and pharmaceutical use | |
| BR0317294A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários | |
| CA2404464A1 (en) | Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders | |
| DE60208568D1 (de) | Prostaglandinanaloga als ep4-rezeptoragonisten | |
| MXPA02012033A (es) | Derivados de 2-aminocarbonil-9h-purina. | |
| WO2004100865A3 (en) | New benzimidazole derivatives | |
| CA2332087A1 (en) | Aryl substituted azabenzimidazoles and their use in the treatment of hiv and aids related diseases | |
| JP2008534453A5 (no) | ||
| UA86776C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение | |
| PE20010541A1 (es) | Uso de una composicion de benzimidazol para tratar el cancer | |
| RU2000104870A (ru) | Производные фталазина и терапевтические средства для эректильной дисфункции | |
| RU98119076A (ru) | Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2 | |
| RU2441021C2 (ru) | Лизобактинамиды | |
| CA2437505A1 (en) | Isoxazoline derivatives as anti-depressants | |
| JP2004534758A5 (no) | ||
| IL160082A0 (en) | Quinoline derivatives and use thereof as antitumor agents | |
| JP2001519413A5 (no) | ||
| CA2523253A1 (en) | Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists | |
| TW200505882A (en) | Benzothiazole derivatives | |
| TNSN00015A1 (fr) | Nouveaux sels de morpholinobenzamide | |
| BR0112957A (pt) | Composto, método de tratamento, uso de um composto, e, composição farmacêutica |